Adapting dose-response methodology to improve clinical trial design for psychotherapies

被引:0
|
作者
Sysko, Robyn [1 ,2 ]
Holland, Katherine [1 ]
Hildebrandt, Tom [1 ]
机构
[1] Icahn Sch Med Mt Sinai, Ctr Excellence Eating & Weight Disorders, Dept Psychiat, New York, NY USA
[2] Icahn Sch Med Mt Sinai, Ctr Excellence Eating & Weight Disorders, 53 East 96 St,Suite 1A, New York, NY 10128 USA
基金
美国国家卫生研究院;
关键词
avoidant restrictive food intake disorder; dose response; psychotherapy; randomized controlled trial; COGNITIVE-BEHAVIORAL THERAPY; EATING-DISORDERS; ANOREXIA-NERVOSA; NATIONAL-SURVEY; IMPLEMENTATION; PSYCHIATRY; EFFICACY; MODEL;
D O I
10.1002/eat.24120
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Objective: Conventional randomized controlled trials (RCTs) have long served as the foundation of research in clinical psychology; however, most treatments for eating disorders show only modest effects on reduction of symptoms and maintenance of long-term remission. New options for psychotherapy treatment development research, beyond continuing to pursue additive or subpopulation approaches, are needed.Methods: One option is to apply dose-response designs, which are commonplace in studies of pharmacology, toxicology, and medical research, and characterized by the evaluation of the amount of exposure (dose) to an intervention, and the resulting changes in body function or health (response).Results: Eating disorder interventions are particularly well-suited for dose-response treatment designs. The deadly nature of eating disorders makes it imperative that patients are not turned away for not being "ready" to engage with treatment. By identifying optimal doses, research will likely yield a more parsimonious course of treatment, which will lend itself to reduced costs, greater uptake, and reduced drop-out.Discussion: Limited use of within-subject designs in trials for patients with eating disorders has produced fast-track efficacy studies and omitted key elements in the treatment development pathway. To decrease reliance on RCT's, dose-response methods should be applied as an alternative study design.Public Significance: Eating disorders are associated with medical and psychiatric comorbidities, poor quality of life, and high mortality. Access to evidence-based services for patients with eating disorders is limited, and identifying additional effective treatment options can be difficult because of challenges inherent to randomized-controlled trials. This manuscript describes an alternative trial methodology to maximize the information that can be gathered prior to utilizing a standard large-scale efficacy design.
引用
收藏
页码:1322 / 1329
页数:8
相关论文
共 50 条
  • [41] Pitfalls in clinical trial design and methodology
    Flather, MD
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 1999, 1 (0R) : R3 - R9
  • [42] Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies
    Siu, Lillian L.
    Ivy, Percy
    Dixon, Erica L.
    Gravell, Amy E.
    Reeves, Steven A.
    Rosner, Gary L.
    CLINICAL CANCER RESEARCH, 2017, 23 (17) : 4950 - 4958
  • [43] Bayesian design for dose-response curves with penalized risk
    Sun, DC
    Tsutakawa, RK
    BIOMETRICS, 1997, 53 (04) : 1262 - 1273
  • [44] CLINICAL DOSE-RESPONSE STUDY OF BACAMPICILLIN IN UNCOMPLICATED GONORRHEA
    BENGTSSON, S
    ERIKSON, G
    KALLINGS, LO
    MOBERG, I
    SANDSTROM, E
    WALLIN, J
    WALLMARK, G
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1979, 5 (02) : 211 - 218
  • [45] APPLICATION OF CONTINGENCY TABLE METHODOLOGY TO DOSE-RESPONSE GROUPED SURVIVAL DATA
    VALULICK, D
    KOCH, GG
    BIOMETRICS, 1978, 34 (04) : 751 - 751
  • [46] Sulphonylurea dose-response relationships: relation to clinical practice
    Lindblad, U
    Melander, A
    DIABETES OBESITY & METABOLISM, 2000, 2 (01): : 25 - 31
  • [47] Dose-Response Determination in Multistage Endpoint Clinical Trials
    Fei Chen
    José Pinheiro
    Therapeutic Innovation & Regulatory Science, 2014, 48 : 56 - 61
  • [48] Biochemical and clinical dose-response curves with sertraline.
    Preskorn, SH
    Harvey, AT
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (02) : PII85 - PII85
  • [49] DOSE-RESPONSE RELATIONSHIP IN CLINICAL ONCOLOGY - CONFERENCE SUMMARY
    BRADE, WP
    FREIREICH, EJ
    GOLDIN, A
    CANCER, 1984, 54 (06) : 1226 - 1228
  • [50] Dose-Response Determination in Multistage Endpoint Clinical Trials
    Chen, Fei
    Pinheiro, Jose
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2014, 48 (01) : 56 - 61